Teclistamab in Relapsed or Refractory Multiple Myeloma

Cancer research · Multiple myeloma

Teclistamab resulted in a high rate of deep and durable response in patients with triple‑class‑exposed relapsed or refractory multiple myeloma.

This is a phase I/II study of the bispecific antibody teclistamab (JNJ‑64007957), which engages T‑cells via CD3 and targets B‑cell maturation antigen (BCMA) on myeloma cells. In 165 heavily pre‑treated patients with triple‑class‐exposed relapsed or refractory multiple myeloma, teclistamab administered weekly by subcutaneous injection (1.5 mg /kg after step‑up doses of 0.06 mg /kg and 0.3 mg /kg) achieved an overall response rate of 63 % and a complete response or better in 39 %. The median duration of response was 18.4 months, progression‑free survival was 11.3 months, and overall survival was 18.3 months. Cytokine release syndrome (CRS) occurred in 72 % of patients and was mostly low‑grade; other common toxicities were neutropenia, anemia, thrombocytopenia and infections.

Tris therapy options are limited in patients whose disease has progressed after exposure to an immunomodulatory agent, a proteasome inhibitor, and an anti‑CD38 monoclonal antibody. Teclistamab offers a new, orally‑administered alternative that can induce deep, durable remissions while having a manageable safety profile (mostly grade I‑II cytokine release syndrome and hematologic toxicities).

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals